The Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta Receives $6M Gift Commitment from CURE Childhood Cancer


$4.5M of CURE’s gift will fully fund the Aflac Cancer Center Precision Medicine Program, which will strive to tailor individualized, non-toxic cancer therapies to pediatric patients

ATLANTA (August 7, 2017)­­-The Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta announces a $6 million gift commitment from CURE Childhood Cancer to support the development of the new Aflac Cancer Center Precision Medicine Program, the Aflac Cancer Center Fellowship Program and 10 childhood cancer research projects.

Over the next three years, $4.5 million of CURE’s gift will go toward the development of the Precision Medicine Program, which will provide personalized, cancer therapies for children. Through the systematic implementation of integrated, comprehensive tumor profiling and the development of novel strategies to identify individual tumors’ vulnerabilities, the Precision Medicine Program will provide state-of-the-art care for children with the highest risk tumors.

“We are so grateful to CURE for this generous gift and their continued support of our patients and researchers as we work to develop new treatments for childhood cancer,” says Douglas K. Graham, M.D., Ph.D., director of the Aflac Cancer Center and professor of pediatrics at Emory University School of Medicine, who will lead the Precision Medicine Program. “Our hope is that we will be able to share the treatments and protocols developed through our program with centers around the country as our new approaches are adopted elsewhere.”

In addition to the Precision Medicine initiative, nearly $1 million of the gift will fund research projects from 10 investigators at the Aflac Cancer Center who will explore new treatments for childhood cancers including neuroblastoma, leukemia and medulloblastoma.

“We are very excited to grow our long standing relationship with the Aflac Cancer Center by fully funding the new Precision Medicine Program,” says Kristin Connor, CURE Childhood Cancer’s Executive Director.  “CURE’s mission is to drive innovative childhood cancer research that will move the needle closer to therapies with fewer side effects for children with cancer and, eventually, cures.  We believe bringing Precision Medicine capabilities to Atlanta is a very important step in advancing our mission.”

The remaining $500,000 of CURE’s gift commitment will be used to fund two fellowships, as well as CURE’s fellowship endowment, and family emergency funds to support families who may be struggling to pay for housing or basic necessities while their child is being treated.

                                                                                                            #

For more information:

Amanda Wade

Public Relations Coordinator

404-785-7741

Amanda.Wade@choa.org

CURE Childhood Cancer

Founded in 1975, Atlanta, Georgia-based CURE Childhood Cancer has raised millions of dollars for research and ongoing education of pediatric cancer and is focused on supporting childhood cancer experts, locally and nationally, who work daily to discover a cure for pediatric cancer. CURE Childhood Cancer currently funds two pediatric oncology Fellows at the Emory University School of Medicine. CURE Childhood Cancer also offers programs that address the critical/urgent needs of patients and their families. For more information go to www.curechildhoodcancer.org or contact Kristin Connor, Executive Director, at 770-986-0035.

Aflac Cancer and Blood Disorders Center of Children’s

The Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta is a national leader among childhood cancer, hematology, and blood and marrow transplant programs, serving children and young adults. Recognized as one of the top childhood cancer centers in the country by U.S. News & World Report, the Aflac Cancer Center cares for more than 450 newly diagnosed cancer patients each year and follows more than 3,200 patients with sickle cell disease, hemophilia and other blood disorders. The Center has a well-developed clinical research office and a robust Phase I/II clinical trials infrastructure. Visit aflaccancercenter.org or call 404-785-1112 or 888-785-1112 for more information.

* Required fields